KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bristol Myers Squibb (BMY) Consolidated Net Income (2016 - 2026)

Bristol Myers Squibb has reported Consolidated Net Income over the past 18 years, most recently at $2.7 billion for Q1 2026.

  • Quarterly Consolidated Net Income rose 8.81% to $2.7 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.3 billion through Mar 2026, up 33.77% year-over-year, with the annual reading at $7.1 billion for FY2025, 178.99% up from the prior year.
  • Consolidated Net Income was $2.7 billion for Q1 2026 at Bristol Myers Squibb, up from $1.1 billion in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $2.7 billion in Q1 2026 and troughed at -$11.9 billion in Q1 2024.
  • The 5-year median for Consolidated Net Income is $1.7 billion (2024), against an average of $893.4 million.
  • Year-over-year, Consolidated Net Income plummeted 625.28% in 2024 and then soared 1328.95% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at $2.0 billion in 2022, then dropped by 12.99% to $1.8 billion in 2023, then crashed by 95.69% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
  • Per Business Quant, the three most recent readings for BMY's Consolidated Net Income are $2.7 billion (Q1 2026), $1.1 billion (Q4 2025), and $2.2 billion (Q3 2025).